Loading clinical trials...
Loading clinical trials...
PADL1NK-005: A Randomized, Phase 3, Open-Label Study to Evaluate PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
Conditions
Interventions
PF-08046054
Docetaxel monotherapy
Locations
305
United States
Alabama Oncology
Alabaster, Alabama, United States
Alabama Oncology
Bessemer, Alabama, United States
Alabama Oncology, Bruno Cancer Center
Birmingham, Alabama, United States
Alabama Oncology
Birmingham, Alabama, United States
Alabama Oncology
Birmingham, Alabama, United States
Alabama Oncology
Birmingham, Alabama, United States
Start Date
September 29, 2025
Primary Completion Date
March 10, 2028
Completion Date
March 10, 2032
Last Updated
April 21, 2026
NCT06498635
NCT07288034
NCT06660407
NCT06500455
NCT03191149
NCT05198830
Lead Sponsor
Pfizer
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions